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PRÁTICA CLINICA
tugal, despite the fact that this country has one of the
lowest incidences of fragility fractures in Western Eu-
rope1. The size of the problem will tend to increase re-
lentlessly due to the increasing ageing of the population
and other societal changes5, unless effective preventive
measures are put in place.
This paper reports on the work of an Expert Com-
mittee convened to foster such measures, by providing
physicians with practical and valid recommendations
regarding the initiation of pharmacological treatment
for osteoporosis and/or the request of DXA evaluation,
in order to optimize the efficiency of interventions and
minimize the costs and risks for individuals and society. 
Since the last publication of recommendations for
the diagnosis and treatment of osteoporosis in Portugal
in 20076, the FRAX® tool has been incorporated in the
clinical guidelines for OP of several countries5,7-12. In
fact, over half of the subjects who experience a fragili-
ty fracture do not have OP as defined by BMD13. FRAX®
integrates a set of well-proven clinical risk facto rs for
fracture, independent of BMD: age, gender, body mass
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IntroductIon 
Osteoporosis (OP) is a metabolic skeletal disease cha -
racterized by low bone mass and microarchitecture de-
terioration leading to increased bone fragility and sus-
ceptibility to fracture. In Portugal, the annual hip
fragility fracture incidence is estimated to be between
154 to 572 per 100.000 women and 77 to 232 per
100.000 men, depending on age1. More than 10.000
patients are admitted every year to the Portuguese Na-
tional Health Service due to hip fragility fractures, jus-
tifying annual total health care expenditures of over
220 million euro2. This corresponded to 1.4% of the to-
tal national health care expenditure in 2013, including
private and public services, according to Portuguese
Health Statistics3. The total expense with fragility frac-
tures is much higher, as hip fractures only account for
about 39.1% of the total number of fragility fractures
observed in Portugal according to a recent study4.
Altogether, osteoporotic fractures currently repre-
sent an enormous social and economic burden in Por-
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index, prior fragility fracture, parental history of hip
fracture, long-term use of oral glucocorticoids,
rheumatoid arthritis and other secondary causes of os-
teoporosis, current smoking and alcohol intake, with
or without BMD. It provides an estimate of the risk of
major osteoporotic fracture (hip, clinical spine,
humerus or wrist fracture) and of hip fracture in the
subsequent 10 years14,15. FRAX® provides valid pre-
dictions without BMD values16,17, although its accura-
cy increases when BMD is also considered18. This al-
gorithm is applied upon the fracture epidemiology and
death rates of each country, to provide locally opti-
mized estimates of fracture probability. The FRAX® was
derived from population-based cohort studies 
from Europe, North America, Asia and Australia and
has been validated in 62 countries and adopted 
by many as the key basis for decisions on whom to
treat.
With this in mind, we have recently validated the
FRAX model for the estimation of osteoporotic frac-
ture probability in the portuguese population –
FRAX®Port15 (http://www.shef.ac.uk/FRAX/tool.aspx?
country=53). Through systematic literature review and
meta-analysis19, as well as consensus discussion we
have decided that FRAX® is the most appropriate ins -
tru ment to achieve similar purposes in Portugal.
Among its advantages lies the possibility of using it
even in the absence of BMD, allowing its output to de-
cide if and when DXA is needed.
We have also performed a nation-wide careful
evalua tion of the costs of hip fractures and their impact
upon quality of life and mortality2. The fracture risk
probabilities above which the different interventions
become cost-effective, in the actual Portuguese 
settings, were defined based on matured economic
methodology, assisted by internationally renowned ex-
perts2. 
These developments laid the optimal ground for a
timely review of the Portuguese recommendations re-
garding the risk threshold for DXA investigation and
pharmacological treatment of osteoporosis.
On these bases, we now recommend that decisions
regarding the performance of dual X-ray absorptiome -
try (DXA) or the initiation of treatment are based on es-
timates of the actual risk of fracture and the econo mic
implications of fractures and the different preventive
strategies. 
This report does not cover all possible management
options and is not intended to override the indivi dual
physician’s responsibility towards the patient or the
personal choice of each patient. The authors wish to
emphasize that formal guidance for every specific si -
tuation or co-morbidity cannot be provided due to lack
of appropriate evidence. Judicious clinical judgment is
required in such conditions.
This work, as well the series of supporting studies
already published or under publication, have been
fun ded by the Portuguese Government through the
Direcção Geral da Saúde – DGS (Portuguese Health
Directorate) following a proposal presented by
Associa ção Nacional Contra a Osteoporose – APOROS
(Na tional Association Against Osteoporosis) and by an
unrestricted grant from Amgen. None of the financial
providers had any involvement in the design of the
studies, interpretation of their results or the content of
derived reports and recommendations.
A total of 10 recommendations were produced
(Table I).
Methods
developMent of guIdelInes
A number of national experts on osteoporosis and all
the relevant Portuguese scientific societies were invi -
ted and accepted to participate in the development of
these recommendations: Rheumatology; Ortho paedics
and Traumatology; Endocrinology, Diabetes and
Metabolism; Gynaecology; Internal Medicine; Physical
and Rehabilitation Medicine; Family Me dicine, Na-
tional Observatory for Rheumatic Disea ses and Portu -
guese Society for Osteoporosis and Metabo lic Bone Di -
seases.  The only national patient organization active
in the field of osteoporosis, Associação Portuguesa
Contra a Osteoporose – APOROS, also participated in
the Committee. Altogether, the Committee had 17 vo -
ting members, all of whom are co-authors of this re-
port.
Relevant questions to be addressed by the recom-
mendations were defined by consensus in a first round
of e-mail consultations upon a draft prepared by the
Principal Investigator (JAPS) and the research fellow
(AM). A thorough literature review was performed in
order to address each question (AM and JAPS) and
made available to the committee members prior to the
meeting. The electronic search was performed in
PubMed MEDLINE (2006- January 15th 2015). The
search strategies included the following medical des -
criptors: “Osteoporosis”, “Osteoporotic fractures”,
“Risk Assessment”, “Algorithms,” “Recommendations”,
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tABle I. suMMAry of recoMMendAtIons on dXA request And IndIcAtIon to treAt In the preventIon
of frAgIlIty frActures 
Average
Recommendation Votes agreement
1 The implementation of general, non-pharmacological, preventive measures for Approved 97.0% 
osteoporosis, such as diet, vitamin D supplementation, exercise, falls prevention 17/17 (75-100)
and monitoring the use of any bone active drug should apply to all ages, whenever favorable
correctable risk factors are identified, irrespective of FRAX® and BMD. votes
2 Pharmacological treatment for osteoporosis should be recommended, unless Approved 95.6% 
contraindicated, in all subjects over the age of 50, who have previously experienced either: 17/17 (70-100)
A.≥1 fragility fracture of the hip or ≥ 1 symptomatic vertebral fragility fracture or favorable
B.≥2 fragility fractures, independently of the site of fracture or the absence of votes
symptoms (e.g. two asymptomatic vertebral fractures). 
3 All Portuguese women and men over the age 50 should have their ten-year risk of Approved 17/17 95.9 % 
osteoporotic fracture estimated with the FRAX®Port tool, with or without DXA. favorable votes (80-100)
4 For FRAX®Port estimates, without DXA, between 7% and 11% for major osteoporotic Approved 16 90.9%  
fracture AND between 2.0% and 3% for hip fracture, BMD of the femoral neck should favorable (60-100)
be obtained and entered into a new FRAX®Port ten-year risk estimation (see Figure 2). votes and one 
DXA may be justified in additional special conditions, as described in text. abstention
5 A. In men and women with a fracture risk estimate (without BMD) below 7% for Approved 16 95.0% 
major osteoporotic fractures AND 2% for hip fracture a decision not to treat with favorable (50-100)
pharmacological agents may be warranted, without the need to perform DXA. votes and one 
Applicable general preventive measures should be applied. abstention
5 B. In such cases, FRAX®Port estimates should be repeated with a frequency that Approved 16 93.8% 
depends on how close the previous estimate is to lower limit of indication to favorable   (60-100)
DXA and also on the occurrence of significant changes in clinical risk factors. and 1
(see Figure 2A). abstention
6 In men and women with a fracture risk estimate, without DXA, above, 11% for major Approved 16 95.3% 
osteoporotic fracture OR 3% for hip fracture, pharmacological treatment with generic favorable (80-100)
alendronate is cost-effective and should be advised (unless contra-indicated), without votes and one 
the need to perform DXA. (see figure 2A). abstention
7 In men and women with a FRAX®Port ten-year risk estimate, including DXA, at or Approved 93.2% 
above 9% for major osteoporotic or 2.5% for hip fractures pharmacological treatment 17/17 (60-100)
for osteoporosis with generic alendronate is cost-effective and should be advised  favorable
(unless contra-indicated). (see Table I and Figure 2B). votes
8 The decision to start anti-osteoporotic treatment with agents other than generic Approved 16 88.1% 
alendronate should be informed by their respective cost-effectiveness thresholds favorable votes (0-100)
(see Table III). and one against 
9 A. In men and women with a FRAX®Port ten-year risk estimate, including DXA, below Approved 96.5% 
9% for major osteoporotic AND below 2.5% for hip fractures, pharmacological agents 17/17 (80-100)
are not cost-effective and a decision not to use them may be warranted. Applicable favorable
general preventive measures should be applied. votes
9 B. In such patients, DXA and FRAX®Port assessments should be repeated every Approved 16  92.8%
2 years or whenever clinical risk factors change significantly (see figure 2). DXA may favorable (75-100)
not be needed in case the previous BMD values are reassuring. votes and one 
abstention
10 While using FRAX®Port for the sake of these recommendations, health professionals Approved 97.6% 
should be aware of several limitations of this tool and considerer judicious adjustments 17/17 favorable (70-100)
of the risk estimates provide by this tool in specific circumstances, described below. votes
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“Guidelines”, ”Treatment”, “Cost-effectiveness”, “Bone
Mineral Density” and “DXA”. Original articles, reviews
and guidelines regarding threshold for treatment initia -
tion and DXA request were included in this review.
Refe rences cited in published Systematic Reviews or in
original articles were also checked. 
Possible alternative answers to the elected questions,
according to the collected evidence, were drafted by
the principal investigator and submitted, together with
the respective evidence, to the Expert Committee in a
second round of emails. Committee members were
asked to appraise the supportive evidence and alterna-
tive recommendations or to propose additional ones.
All alternatives were circulated in a third round of 
e-mails, prior to the final face-to-face meeting.
This meeting was held on the 13th March 2015 to
discuss the generated evidence, vote on the possible
answers and thus generate a set of recommendations.
The meeting was recorded for documentation and fu-
ture clarification of doubts. The votes of individual re -
presentatives and degree of agreement regarding each
recommendation were registered. Portuguese data on
the cost-effectiveness of interventions according to dif-
ferent fracture risk thresholds were disclosed to the
panel, for the first time, only after all the guiding prin-
ciples, presented below, had been irrevocably esta -
blished. They were only known to three of the mem-
bers, who performed the study (AM, OL, JAPS). This
strategy was adopted to guarantee that the cost-effecti -
veness basis for the decision to intervene was based on
the grounds of guiding principles and not contamina -
ted by considerations of the percentage of the popula-
tion eligible for intervention, its overall costs, or the
(dis)similarity of our intervention thresholds vis-a-vis
other published guidance.
A final round of e-mails was conducted to refine
some recommendations. 
Finally, this paper was drafted and circulated among
the committee members until a final version was
reached and submitted to the individual societies’ and
associations’ approval and endorsement. 
underlyIng conceptuAl defInItIons:
guIdIng prIncIples
As a preparatory phase for the definition of the recom-
mendations, the Committee planned and developed a
detailed discussion dedicated to the establishment of a
number of guiding principles and concepts. These are
presented below:
guIdIng prIncIple 1 
Risk factors for osteoporosis, as those related
with diet, exercise, sun exposure, medications,
should be assessed by health professionals and
patients throughout life, and corrected when
appropriate 
This guiding principle was approved by all committee
members 17/17 votes.
Many risk factors for osteoporosis influence bone
health from the earliest phases and throughout life,
even if the consequences of osteoporosis only become
apparent later in life. This is the case, for example, of
diet (calcium, protein), exercise, vitamin D status, and
medications such as glucocorticoids. All these condi-
tions have health implications far beyond the limits of
bone health and should, therefore, be considered as a
medical routine. The correction of these risk factors is
an integral part of osteoporosis management, usually
referred to as “General Measures”. 
guIdIng prIncIple 2 
The decision to institute pharmacological
treatment in osteoporosis should be based on 
the individual’s ten-year risk of subsequent
osteoporotic fracture as estimated by the
FRAX®Port tool
This guiding principle was approved by all committee
members 17/17 votes
FRAX® is an algorithm developed by the Centre for
Me tabolic Bone Diseases, University of Sheffield, UK,
which allows the estimation of the individual risk of
osteoporotic fractures over the subsequent 10 years on
the basis of 11 clinical risk factors (CRFs) that have
been shown, through individual studies and meta-ana -
ly ses, to influence the risk of fracture, independently of
BMD. They are all easily available in clinical practice:
age, weight, height, prior fragility fracture, parental his-
tory of hip fracture, current tobacco smoking, ≥ 3
months glucocorticoids use, rheumatoid arthritis, cau -
ses of se condary osteoporosis (type I diabetes, osteoge -
nesis imperfecta in adults, untreated long-standing hy-
perthyroidism, hypogonadism or premature menopau-
se (<45 years), chronic malnutrition, or malabsorption
and chronic liver disease) and alcohol consumption.
FRAX® can be used with or without BMD (Figure 1). 
When calculated using only CRFs, i.e, without con-
sidering BMD, FRAX® has been shown to have a better
performance than BMD alone in predicting major frac-
ture risk20. The development of this tool was based on
excellent methodology14 and its validity has been ex-
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ternally confirmed, up until now, by twenty-six stu dies
performed in different countries and cohorts14,21-43. A
total of 62 countries and/or ethnic models, are cur-
rently available and several others are being developed5.
A recent systematic literature review and meta-
analy sis performed by some of the Committee mem-
bers19 clearly demonstrated that FRAX is the most ro-
bust and accessible tool available to predict the risk of
osteoporotic fractures. Its accuracy is well established
and demonstrated by area under the curve (AUCs)
from receiver operating characteristic (ROC) analysis
for fractu re prediction that range from 0.71 to 0.79 in
meta-analysis. This performance in only surpassed by
the QFracture tool19, but this instrument requires the
consideration of 31 clinical risk factors and has only
been validated for the UK and Ireland.
The FRAX®Port tool is the Portuguese version of
FRAX®, developed to incorporate the actual epidemio -
logy of hip fractures and mortality in the general Por-
tuguese population15. The methodology and results of
this adaptation have been endorsed by the Sheffield
University department responsible for FRAX® and by
all Portuguese scientific societies and patients’ organi-
zations related to osteoporosis. It is readily available
online.
guIdIng prIncIple 3 
The presence of previous fragility fractures
justifies the consideration of pharmacological
treatment, irrespective of the risk-estimate by
the FRAX®Port tool
This guiding principle was approved by 15 favorable
votes, one against and one abstention.
Several studies support the conclusion that it is cost-
-effective to treat individuals with a prior hip or verte-
bral fragility fracture8,9,44. Vertebral fractures, for exam-
ple, are a very strong risk factor for subsequent hip and
vertebral fracture45,46, whereas forearm fractures pre-
dict future vertebral and hip fractures47. 
The vote against was justified on the basis that pre-
vious fractures are already accounted for in FRAX®.
The time elapsed since the last previous fracture is
fIgure 1. Screen page for input of data and risk estimation in the Portuguese version of the FRAX® tool (Portuguese model, version
3.9. http://www.shef.ac.uk/FRAX/tool.aspx?country=53)
[With permission of the Centre for Metabolic Bone Diseases, University of Sheffield Medical School, UK]
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also relevant: the risk of further fractures is greatest
during the first 2–3 years but remains significantly ele -
vated for up to 10–15 years (most notably for proximal
femoral fractures, vertebral fractures, and hume ral frac-
tures) 48,49.
guIdIng prIncIple 4
Physicians should be aware of the limitations 
of FRAX® and of DXA, and make judicious
informed adaptations of the fracture risk
estimate when such limitations apply
This guiding principle was approved by all committee
members 17/17 favorable votes.
guIdIng prIncIple 5 
Portuguese intervention thresholds should be
based on a similar FRAX® ten-year risk estimate
for all ages. This principle should only be
overruled if the health-economics evaluations
demonstrated that the intervention threshold for
any given age&gender group differs more than
50% from the value recommended on the basis 
of the overall population
This guiding principle was approved by 10 of the 17 com-
mittee members, 4 voted against and three abstai ned.
This was one of the most controversial points in the
consensus meeting. The final recommendation is simi -
lar to the guidelines adopted by the National Osteo-
porosis Foundation – USA12 and Canada11. In both the -
se cases, the threshold for intervention was defined as
the level of risk above which the cost per QALY gained
was within the national acceptable limits. In both these
guidelines, a similar value of estimated risk of fracture
was adopted as the threshold for intervention for all
ages and both genders, despite there being small age-
and gender-related differences in the levels of risk that
defined cost-effectiveness. 
The recommendations issued by the United King-
dom’s Royal College of Physicians44, the Swiss associa-
tion Against Osteoporosis9 and the French National Au-
thority for Health7 adopted a different conceptual drive:
Treatment is recommended for all people whose 10-
-year FRAX® estimated risk is equal or superior to that
of a female patient of similar age, who has already suffe -
red a fragility fracture. This concept is based on the fact
that treatment in people with a previous fragility frac-
ture has been shown to be cost-effective. Given that the
risk of fracture increases with age, all other things 
being equal, this approach determines that the inter-
vention threshold increases substantially with age. As
an example, according to the UK guidance referred
above, treatment will be recommended for a 50 year
old whose 10-year risk of fracture is 7.5% but not for
a 70 year-old whose ten-year estimated risk is 24%.
The majority of our committee refused this philoso -
phical approach. This was based mainly on the argu-
ment that the gain of one Quality-adjusted life year
(QALY) should be considered of the same value for all
ages. It was emphasized that age, as well as mortality
are already considered in FRAX® and thus influence
the fracture risk estimate. Overall, the majority of the
committee decided to stand by the concept that, for
the sake of equity, similar gains in health, as measured
by QALYs, should justify similar financial efforts by so-
ciety, irrespective of age.
guIdIng prIncIple 6 
The Portuguese intervention thresholds 
should be based on cost-effectiveness data
This guiding principle was approved by all committee
members 17/17 votes.
By doing this, the Committee decided to accept that
the threshold for intervention, at a population level,
should be informed by economic considerations, rather
than on a «political» perspective of a level of risk that
would justify intervention, irrespective of its costs and
societal willingness to pay. The committee thus
acknow ledges that the cost of intervention and the so-
cietal willingness to pay needs to be taken into account
in decisions to treat or not to treat.
This principle implies that decisions to treat should
have a similar foundation in all realms of medicine in
our country – the impact of interventions in terms of
QALYs gained should be calculated, the cost per QALY
gained (or Incremental Cost-Effectiveness Ratio –
ICER) determined and, naturally, a similar willingness
to pay for a QALY should be applied, whatever the di -
sease and intervention under consideration.
guIdIng prIncIple 7
The intervention thresholds should be 
based on data reflecting the Portuguese 
reality on fractures, mortality, costs and
treatment efficacy
This guiding principle was approved by all committee
members 17/17 votes.
Recommendations on the level of fracture risk above
which pharmacological intervention become cost-ef-
fective are inextricably dependent on dimensions that
vary enormously at a national level, such as: epidemio -
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logy of fractures, general mortality, mortality associa ted
with fractures, medical interventions used in fracture
cases, costs of caring for fractures, costs of preventive
interventions, health policies, cost per QALY gained
(ICER), economic status of the country and willingness
to pay. This imposes the need to consider national data
when making such decisions, and requires that inter-
vention-threshold recommendations for Portugal had
to wait until such data became available.
guIdIng prIncIple 8 
The threshold for pharmacological treatment 
of osteoporosis shall be established at ten-year
risk estimates that correspond to a Willingness
to Pay per QALY gained of €32,000. 
The cheapest of all pharmacological interventions
should be taken as the basis to decide on the 
actual intervention threshold for the Portuguese
population.
This guiding principle was approved by 16 com-
mittee members and one abstention.
Cost-effectiveness of a given intervention can only be
established by comparing its impact to a set value of will-
ingness to pay for a QALY gained50. There is no esta -
blished Portuguese national policy establishing Willing-
ness to Pay for QALYs. So, the panel decided to endorse
the recommendations issued by WHO, that this should
be set at 2 fold the National Gross Product per capita51 –
32.000€ is a rounding up of 2 × 16.400€, the Portuguese
Gross domestic product (GDP) for year 201452. 
The choice for the cheapest intervention as a refer-
ence is based on the fact that the costs as well as the ef-
fectiveness of each of the available alternatives are ta -
ken into account while establishing the respective Cost
per QALY (ICER).
All the above decisions were made before the ac tual
cost-effectiveness studies for Portugal were presented
to the Committee. 
guIdIng prIncIple 9 
DXA should be performed when it has 
a reasonable probability of changing the 
decision to treat/not to treat that can be 
taken on the basis of the FRAX®Port risk
estimation made without DXA
This guiding principle was approved by 16 favorable
votes and one abstention.
Adding DXA to CRFs in FRAX® results, according to
our meta-analysis, in the improvement of the AUC
from 0.74 to 0.7919. DXA may also assist the clinician
in gauging the probability of secondary osteoporosis, in
quantifying response to therapy and motivating the pa-
tient to treatment. The Committee considered that per-
forming one DXA examination, at the time of deciding
whether to treat, represents a relatively minor cost in
view of the overall burden of the disease, which is com-
pensated by the benefits than can be derived from that
exam. This perspective led to a less stringent recom-
mendation on when to perform DXA. 
Based on this guiding principle the following 
concepts were defined for the purposes of these 
recommendations:
• Intervention threshold: A FRAX®Port ten-year
risk-estimate value, with BMD, above which pharma-
cological treatment is warranted.
• Range of fracture risk indicating the need for
DXA: A range of FRAX®Port ten-year risk-estimate,
without BMD, within which DXA is justified, because
it holds a reasonable probability of changing the deci-
sion to treat or not-to-treat.
Ideally, the lower and upper threshold for DXA evalua -
tion would be based on real life Portuguese data esta -
blishing the probability of BMD inducing a change in the
decision to treat/not to treat, around the intervention
threshold. In the absence of such data, and ta king into ac-
count the issues described above, the Committee con-
sensually decided to establish these values at 2% and
0.5% above and below the intervention thre shold for ma-
jor osteoporotic and for hip fractures res pectively.
cost-effectIveness AnAlysIs
Once the above Guiding Principles were adopted, the
Portuguese cost-effectiveness analysis with generic
alen dronate (the less expensive intervention) versus no
treatment was presented to the Committee (Table II). 
A detailed study in a representative sample of Por-
tuguese patients with hip fractures was performed to
establish the impact of osteoporotic fractures in terms
of resource consumption (direct and indirect costs),
mortality and quality of life. A societal perspective was
adopted, i.e. all costs were considered irrespective of
the payer being the patient or the security system2. 
These data were incorporated in a previously vali-
dated Markov economic model53 which synthetized re -
levant available data, such as the incidence of fractures
and their age distribution, the general population mor-
tality, the cost, effectiveness and risk of adverse events
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of the different medications, need for co-medications
and control procedures and drop-out rates. This mo -
del allows the estimation of Incremental Cost-Effec-
tiveness Ratio – ICER, for each intervention, a concept
that can be understood as the cost paid for each QALY
gained, in comparison to no treatment. The results
were used to establish the levels of estimated risk of
fracture at which each given intervention becomes cost
effective, i.e. results in costs per QALY within the es-
tablished willingness to pay.
Based on the published results54, the Committee de-
cided to adopt the FRAX®Port risk estimates of 9% for
major osteoporotic fractures and 2.5% for hip fractures
as the intervention thresholds for generic alendronate,
in Portugal – Table II. The values for assessment thresh-
old were established as 2% and 0.5% above and below
the threshold of intervention for major osteoporotic or
hip fractures, respectively.
recoMMendAtIons
recoMMendAtIon 1
The implementation of general, 
non-pharmacological, preventive measures 
for osteoporosis, such as diet, vitamin D
supplementation, exercise, falls prevention 
and monitoring the use of any bone active drug
should apply to all ages, whenever correctable
risk factors are identified, irrespective of 
FRAX® and BMD 
This recommendation was approved by all committee
members the 17/17 votes and an average agreement of
97 % (mín.-máx.= 75-100) .
recoMMendAtIon 2
Pharmacological treatment for osteoporosis
should be recommended, unless
contraindicated, in all subjects over the age 
of 50 who have previously experienced either: 
A. ≥ 1 fragility fracture of the hip or ≥1
sympto matic vertebral fragility fracture or 
B. ≥ 2 fragility fractures, independently of the
site of fracture or the absence of symptoms (e.g.
two asymptomatic vertebral fractures). 
This recommendation was approved by all committee
members the 17/17 votes and an average agreement of
95.6 % (70-100).
Specifications to Recommendation 2
For this purpose, a fragility fracture is defined as a frac-
ture occurring spontaneously or following minor trau-
ma, i.e similar or inferior to that of a fall from body
height, after exclusion of pathological local causes of
fracture such as neoplasia.
This recommendation implies that the presence of
such fractures overrides the FRAX®Port, i.e treatment
should be considered in these patients irrespective of
FRAX®Port risk-estimate or DXA measurements. This
does not imply that FRAX® or DXA should not be per-
formed, as they may provide useful information to
guide further investigation and choice of therapeutic
interventions.
Recommending treatment for people who have al-
tABle II. cost-effectIve InterventIon thresholds eXpressed As the 10-yeAr proBABIlIty of A
MAjor /hIp frActure (%) At whIch InterventIon wIth generIc AlendronAte BecoMes cost-effectIve
In coMpArIson to no treAtMent, AdoptIng A wIllIngness to pAy of €32,000.00/qAly 
Age 10-year probability of a major fracture (%) 10-year probability of a hip fracture (%)
50 8.6 2.6
55 8.7 2.4
60 10.4 3.0
65 9.2 2.3
70 8.6 2.3
75 8.1 2.1
80 7.1 1.7
85 5.9 1.3
All ages 8.8 2.5
The intervention threshold for “All ages” is not the arithmetic mean of the individual age-groups values but the result of QALY calculations
including the overall population. Adapted from 54
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ready endured a fragility fracture, irrespective of FRAX®
is common to all of the abovementioned recom -
mendations: NOF-USA8 Canada11, France7 and
Switzerland9. This concept is inherent to the NOGG/
/UK recommendations44. The exact definition varies be-
tween documents. No evidence was found to propose
the inclusion of ≥ 2 fragility fractures (other than hip
or clinical vertebral) for treatment without further as-
sessment. This was a consensus recommendation,
based on the authors’ opinion and experience.
recoMMendAtIon 3
All Portuguese women and men over the 
age 50 should have their ten-year risk of
osteoporotic fracture estimated with the
FRAX®Port tool, with or without DXA
This recommendation was approved by all committee
members 17/17 votes and an agreement of 95.9 % (80-
-100).
Specifications to recommendation 3
The decision to perform DXA should, ideally, be based
on this initial FRAX®Port without BMD, as described
below. However, if a recent BMD is already available, its
value should be entered in the FRAX®Port calculation.
The decision process for treatment should, in such case,
be based on Recommendations 7, 8 and 9. DXA values
can be acceptable for this purpose for up two years,
unless significant events for bone metabolism take
place meanwhile.
Physicians are strongly recommended to strictly
adhe re to the definitions of clinical risk factors as des -
cribed in the FRAX® website.
recoMMendAtIon 4
For FRAX®Port estimates, without DXA,
between 7% and 11% for major osteoporotic
fracture and between 2% and 3% for hip 
fracture, BMD of the proximal femur, and, if
possible and indicated, the spine should be
assessed and the results of femoral neck 
T-score entered into FRAX®Port. (Figure 2). 
DXA may be justified in additional special
conditions, as described below.
This recommendation was approved by 16 favorable
votes and one abstention with an average agreement of
90.9 % (60-100).
Specifications to recommendation 4
For the purposes of this recommendation, BMD should
be assessed by dual x-ray absorptiometry (DXA).
The spine and proximal femur, are the sites recom-
mended for DXA evaluation55. Spine DXA is prone to
overestimate BMD in the presence of osteoarthritis, ver-
tebral fractures and other calcifying changes overlaying
the sites of interest.
The T score value for the femoral neck should be
used for FRAX®Port.
In the context of decision to/not-to treat, DXA re-
sults must be considered in the context of FRAX®Port
and not in isolation. This principle implies that the di-
agnosis of osteoporosis or osteopenia based on densito -
metry does not, per se, warrant the initiation of phar-
macological treatment for osteoporosis.
The use of DXA for monitoring therapy is contro-
versial, it is rarely justifiable at intervals of less than 
2-3 years and may be dispensable altogether if the 
fIgure 2. Use of FRAX®Port ten-year estimated risk of major osteoporotic and hip fractures to decide on request of DXA and on
initiation of pharmacologic treatment for osteoporosis. A: Estimates without BMD. B. Estimates with BMD.
A B
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adherence to effective therapy is guaranteed (for more
info on the appropriate use and interpretation of DXA
see references18,56,57).
The committee considers that performing DXA may
occasionally be justified outside these FRAX bound-
aries or irrespective of them, including in the condi-
tions described in Table III.
Other conditions, with less well-established rela-
tionship with osteoporosis, may also justify the per-
formance of DXA as part of the diagnostic work-up.
These include Cystic fibrosis; Ehlers-Danlos; Gau cher’s
disease; Glycogen storage diseases; Hemo chromatosis;
Homocystinuria; Hypophosphatasia; Marfan syn-
drome; Menkes steely hair syndrome; Porphyria; Ri-
ley-Day syndrome; Athletic amenorrhea; Hyperpro-
lactinemia; Panhypopituitarism; Turner’s and Klinefel-
ter’s syndromes; Cushing’s syndrome; Thyrotoxicosis;
Gastric bypass; Gastrointestinal surgery; Pancreatic 
di sease; Primary biliary cirrhosis; Hemophilia;
Leukemia; Lymphomas; Monoclonal gammopathies;
Multiple myeloma; Sickle cell disease; Systemic mas-
tocytosis; Thalassemia; Ankylosing spondylitis; Sys-
temic lupus erythematosus; Amyloidosis; Chronic
metabolic acidosis; Chronic obstructive lung disease;
Congestive heart failure; Depression; End-stage renal
disease; Hypercalciuria; Idiopathic scoliosis; Post-
-transplant bone disease; Sarcoidosis; type I diabetes
mellitus. 
Some medications with less well-established rela-
tionship with osteoporosis, may also justify the per-
formance of DXA in special cases. These include: Alu-
minum (in antacids); Anticoagulants (heparin); Barbi-
turates; Cancer chemotherapeutic drugs; Depo-
medroxyprogesterone; Lithium; Cyclosporine A and
tacrolimus; Methotrexate; Parental nutrition; Proton
pump inhibitors; Selective serotonin reuptake in-
hibitors; Tamoxifen®; Thiazolidinediones (such as Ac-
tos®); Thyroid hormones (in excess).
recoMMendAtIon 5
A. In men and women with a fracture 
risk estimate (without BMD) below 7% for 
major osteoporotic fractures and 2% for hip
fracture a decision not to treat with
pharmacological agents may be warranted,
without the need to perform DXA.
Applicable general preventive measures 
should be applied
This recommendation was approved by 16 favorable
votes and one abstention with an average agreement of
95 % (50-100).
B. In such cases, FRAX®Port estimates 
should be repeated with a frequency that 
depends on how close the previous estimate 
is to lower limit of indication to DXA and 
also on the occurrence of significant changes 
in clinical risk factors. (Figure 2a)
This recommendation was approved by 16 favo rable
votes and one abstention with an average agreement of
93.8 % (60-100).
Regarding recommendation 5B the Committee pre-
sumes that FRAX®Port reassessments will, on average,
in such cases, be justified every 5 years from age 50 to
70 and every two to three years thereafter, in the ab-
sence of relevant intercurrences.
recoMMendAtIon 6
In men and women with a fracture risk 
estimate, without DXA, above, 11% for major
osteoporotic fracture or 3% for hip fracture,
pharmacological treatment with generic
alendronate is cost-effective and should be
advised (unless contra-indicated), without 
the need to perform DXA. (Figure 2a)
This recommendation was approved by 16 favorable
tABle III. condItIons/dIseAses And 
treAtMents wIth IMpAct upon BMd, 
As estABlIshed By systeMAtIc lIterAture
revIews And/or MetA-AnAlysIs
Patients with the following Patients starting or under 
conditions/diseases the following medications
Fragility fracture age Androgen deprivation 
≤50 years (58) therapy (59-61)
Prolonged immobilization Glucocorticoids (64)
and paralysis(62, 63)
Falls history (5, 6, 8, 11, 18) Anticonvulsants (65)
Anorexia nervosa (66, 67) Gonadotropin-releasing 
hormone analogues
(GnRH) (68-70)
Calcium and vitamin D Aromatase inhibitors 
deficiency (5, 8, 71, 72) (73-77)
Intestinal malabsorption Antiretroviral therapy 
(8, 78) (72, 79)
Rheumatoid arthritis (80)
Hyperparathyroidism (81, 82)
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votes and one abstention and an average agreement of
95.3 % (80-100).
recoMMendAtIon 7
In men and women with a FRAX®Port 
ten-year risk-estimate, including DXA, 
at or above 9% for major osteoporotic or 2.5%
for hip fractures pharmacological treatment 
for osteoporosis with generic alendronate is 
cost-effective and should be advised (unless
contra-indicated). 
(See Table II and Figure 2B) 
This recommendation was approved by all committee
members 17/17 votes with an average agreement of
93.2 % (60-100).
recoMMendAtIon 8
The decision to start anti-osteoporotic 
treatment with agents other than generic
alendronate should be informed by their
respective cost-effectiveness thresholds 
(Table IV) 
This recommendation was approved by 16 favorable
votes and one against with an average agreement of
88.1 % (0-100).
Specifications to recommendation 8
This recommendation does not preclude the decision
to prescribe these medications at lower risk-estimates,
based on clinical grounds, such as formal-contraindi-
cation to less expensive alternatives, or conditions ma -
king the selected choice especially appropriate. The in-
dividual physician may also decide to adopt a different
willingness to pay.
This specification was approved by 16 favorable
votes and one against and an average agreement of
99.3% (90-100).
The cost per QALY associated with different medica -
tions is affected by their cost and effectiveness in diffe -
rent clinical settings. IV presents the risk-estimate 
le vels at which treatment with zoledronic acid, deno-
sumab and teriparatide become cost-effective in com-
parison to no-treatment and may, thus, be recommen -
ded on cost-effectiveness grounds, as described by Mar-
ques et al54.
The authors want to highlight that no national 
data is available on cost-effectiveness thresholds for
other drugs. The only alternative is to extrapolate based
on indicators of effectiveness, persistence and cost 
of those alternative drugs compared to the studied 
options.
recoMMendAtIon 9
A. In men and women with a FRAX®Port 
ten-year risk estimate, including DXA, 
below 9% for major osteoporotic and 
below 2.5% for hip fractures, pharmacological
agents are not cost-effective and a decision 
not to use them may be warranted. 
Applicable general preventive measures 
should be applied
This recommendation was approved by all committee
members the 17/17 votes and an average agreement of
96.5 % (80-100).
B. In such patients, DXA and FRAX®Port
assessments should be repeated every 
2 years or whenever clinical risk factors 
change significantly (Figure 2). 
DXA may not be needed in case the previous
BMD values are reassuring
This recommendation was approved by 16 favorable
votes one abstention and an agreement of 92.8% (75-
-100).
tABle Iv. cost-effectIveness thresholds for severAl MedIcAtIons, BAsed on the frAX®port 
ten-yeAr osteoporotIc frActure rIsk estIMAte, BAsed on A wIllIngness to pAy of 32.000€/qAly
And current cost of MedIcAtIon. AdApted froM 54
Without DXA With DXA
Cost basis/year (€) Major % Hip % Major % Hip %
Generic alendronate 99 11 3 9 2.5
Zoledronic acid 347 22 12 20 10
Denosumab 552 37 25 35 23
Teriparatide 4234 80 65 78 63
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recoMMendAtIon 10
While using FRAX®Port for the sake of these
recommendations, health professionals should 
be aware of several limitations of this tool and
considerer judicious adjustments of the risk
estimates provide by this tool in specific
circumstances, described below 
This recommendation was approved by all committee
members the 17/17 favorable votes with an average
agreement of 97.6 % (70-100).
Specifications of recommendation 10  
1. The limitations of FRAX®Port are the same as those
of FRAX®. Some of these may be resolved in future
revisions of the tool;
2. FRAX® does not take into account the number of
prior fragility fractures18, but this limitation is over-
come by the Committees decision to recommend
previous fragility fracture as an independent criteri-
on to start treatment. 
3. FRAX® has not been validated to be used in patients
under osteoporotic treatment or for monitoring the
effects of treatment18.
This specification was approved by 16 favorable votes,
one abstention and an average agreement of 100%.
4. Falls are an important clinical risk factor for frac-
tures and are not included in the FRAX® tool9. No
formal recommendation can be made for this pur-
pose, due to lack of appropriate scientific evidence.
The best reference values that we can be provided are
based on calculations performed with the QFrac-
ture®201383, a validated and accurate fracture risk
estimation tool, which considers falls.  In this con-
text, the presence of a “history of falls”, multiplies by
a factor of around 1.5, the 10-year fracture risk es-
timate made in its absence.
This specification was approved by 17 favorable
votes and an average agreement of 92.1 % (0-100).
5. The FRAX tool does not take into account the corti-
costeroid dose above 5mg Prednisolone equivalent
for three months. The Committee recommends that
the 10-year probabilities of a hip fracture or a major
osteoporotic fracture be adjusted according to the
dose of glucocorticoids as described in Table V. No
adjustments regarding duration of treatment can be
proposed, due to lack of appropriate evidence.
This specific recommendation was approved by 16
favorable votes, one abstention and an average agree-
ment of 87.5% (50-100). 
6. FRAX® algorithm uses T-score for femoral neck BMD
and does not take into account the lumbar spine
BMD. However, when there is a large discordance
(> 1SD) in the T-score of femoral neck and lumbar
spine, it is proposed that the clinician may in-
crease/decrease FRAX® estimate for major osteo-
porotic fractures by 10% for each rounded T-score
difference between the lumbar spine and femoral
neck5, 85. 
For example if T-score femoral neck = -1.5 and 
T-score lumbar spine = -2.8, the FRAX® estimate for
major osteoporotic fractures should be increased by
10% percent (for example from 7% to 7.7%). If the
va lues were -1.5 and -1.9 respectively, no changes
should be made (difference <0.5 T). If femoral neck
T score = -2.3 and lumbar spine T score = -3.9, the
difference (1.6) is rounded to 2 T score and the ma-
jor osteoporotic fractures risk estimate should be in-
crease by 20% (for example from 8% to 9.6%, jus-
tifying medication accor ding to the present recom-
mendations). 
As in all other circumstances, it is important to
guaran tee the quality and validity of lumbar spine
DXA.
This specification was approved by 17 favorable
votes and an agreement of 91.5% (75-100).
In Figure 3 we present a simplified integrated flow
chart of decisions on treatment and DXA assessment
according to the current recommendations. Take into
account that the intervention thresholds are based on
calculations for generic alendronate. Please refer to re -
commendation 8 to adapt for other medications.
tABle v. recoMMended AdjustMent of 
10-yeAr proBABIlItIes for MAjor 
osteoporotIc frActure or hIp frActure for
All Ages, AccordIng to dAIly dose of 
glucocortIcoIds. AdApted froM 5,84. 
MultIply the frAX®port frActure rIsk 
estIMAte By the provIded AdjustMent fActor
Adjustment factor for ten 
year-probability estimates 
(for all ages)
Prednisolone Major osteoporotic Hip 
equivalent (mg/day) fracture fracture
<2.5 0.8 0.65
2.5–7.5 No adjustment
≥7.5 1.15 1.20
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dIscussIon And fInAl reMArks
Ten recommendations regarding who to treat for os-
teoporosis and who to examine with DXA in daily cli -
nical practice have been developed for Portuguese pa-
tients, based on consensualized guiding principles and
updated epidemiologic and economic evaluations in
the Portuguese setting (Table I). The recommendations
are practical, evidence-based and supported by a pa nel
of experts and representatives of all Portuguese scien-
tific societies and patients’ associations with an inte rest
in Osteoporosis.
Evidence was used as the basis for recommendations
as much as possible and this was supplemented by col-
legial decisions of the experts when decisive evidence
was lacking. Considerable effort was put in to trying to
keep the recommendations as simple, but also com-
prehensive, i.e capable of responding to most of the
practicing clinicians needs. 
These recommendations provide a much more ro-
bust and rationale basis for treatment decisions than
considering solely the bone mineral density (BMD) or
asking clinicians to base decisions on a subjective
weighting of clinical risk factors. FRAX® allows the in-
Subjects over the age of 50 who have previously experienced≥1 fragility fracture of the HIP, or ≥1 clinical vertebral fracture or≥2 any fragility fractures
NO Yes
FRAX® PortWithout BMD
Follow-up*Generalmeasures
<9% Majorand<2.5% Hip ≥ 9% Majoror≥ 2.5% Hip
Considertreatment
FRAX® PortWith BMD
DXA
≤ 7% Majorand≤ 2% Hip Intermediate ≥ 11% Majoror≥ 3% Hip
Subjects over the age of 50 who have previously experienced≥1 fragility fracture 
of the HIP, or ≥1 clinical vertebral fracture or≥2 any fragility fractures
NO Yes
FRAX® Port
Without BMD
Follow-up*
General
measures
<9% Major
and
<2.5% Hip
≥ 9% Major
or
≥ 2.5% Hip
Consider
treatment
FRAX® Port
With BMD
DXA
≤ 7% Major
and
≤ 2% Hip
Intermediate
≥ 11% Major
or
≥ 3% Hip
fIgure 3. Integrated approach of osteoporosis intervention thresholds and DXA request for Portuguese patients according to the
current recommendations. Intervention thresholds described in this figure are appropriate for generic alendronate. Consider 
recommendation 8 (Table IV) for other agents. 
BMD = bone mineral density; DXA= Dual-energy X-ray absorptiometry; *Follow up – Repeat assessments as suggested in 
recommendations 5B and 9B
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tegration of a large number of clinical risk factors for
fractures, whose relevance has been proven by evidence
and whose impact has been estimated by meta-analy-
sis. Moreover, the Portuguese version of FRAX incor-
porates the actual epidemiology of fragility fractures
and mortality in the target population. The considera-
tion of cost-effectiveness analyses of interventions in
our actual epidemiologic and economic context, res -
ponds to the res ponsibility of making judicious use of
the limited resources available for health care. These
calculations were performed using state-of-the-art eco-
nomic models and prestiged economic counseling. The
adopted willingness to pay follows international re -
commendations.
A certain degree of arbitrariness was used in esta -
blishing the same cost-effective intervention threshold
for all ages, despite there being considerable variabili-
ty between the age groups. The same applies to the
amount adopted as willingness to pay (WTP): some
practitioners may have a different view and the WTP
may change according to GDP and national health poli-
cies.  Expert users may wish to produce a more precise
definition of cost-effective threshold for specific indi-
vidual cases, taking into account the patient’s age, the
medication being considered or a WTP of their own
choice. This can be achieved through the use of a dedi-
cated tool made available by Marques et al54 https://dl.
dropboxusercontent.com/u/4287154/OsteoporoseThr
Calc/ThreshComputationPortugalFINAL. xlsm.
These recommendations represent an important
paradigm shift, which was made possible by the de-
velopment of FRAX®, its Portuguese adaptation and the
economic evaluations described above. We believe that
the potential of this change towards supporting a more
efficient use of human and financial resources in the
combat to the ever-growing epidemics of osteoporotic
fractures is truly enormous. However, it all depends on
the use that health professionals, both individually and
as a community, make of these new tools. It is expect-
ed that the endorsement of these recommendations by
all the experts and societies represen ted will increase
their dissemination and implementation into national
clinical practice, thus expanding their potential to fos-
ter progress on the current standard of osteoporosis
management in our country.
We will be greatly indebted to all health profession-
als who may be willing to share their views and expe-
riences on using these recommendations and offer sug-
gestions on how to improve their reach on behalf of
public health (reuma@huc.min-saude.pt)
This article has been copublished in the issue no. 6 of
Revista Portuguesa de Medicina Geral Familiar (Rev
Port Med Geral Fam 2016; 32:425-441).
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